Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Danazol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 3/20 | 1.00 |
| ▸ | AR known ✓ | P10275 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | SHBG | P04278 | 4/20 | 1.00 |
| ▸ | ESR1 | P03372 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Danazol SCHEMBL14045163 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL5021653 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL5499397 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL13184574 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL7722243 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL23468175 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL5248054 | 0.99 | CYP3A4 (0.98) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL27720831 | 0.96 | CYP3A4 (0.93) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL4780325 | 0.93 | LMNA (0.86) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL3146698 | 0.89 | CYP3A4 (0.80) | CYP3A4LMNATSHRCYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 17594 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139065-A1 | TREATMENT OF AIHA WITH BAFF OR BAFF RECEPTOR INHIBITORY ANTIBODIES | NOVARTIS AG (CH) | 2026-05-21 | — | — | US | claimed |
| CN-122063219-A | Method for simultaneously measuring 31 stimulant substances in complex matrix cosmetics | 国家体育总局反兴奋剂中心(中国反兴奋剂中心) | 2026-05-19 | — | — | CN | claimed |
| WO-2026099483-A1 | A READY-TO-USE DRUG DELIVERY SYSTEM | SEVER PHARMA SOLUTIONS (SE) | 2026-05-15 | — | — | WO | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260098088-A1 | ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS | DISC MEDICINE, INC. (US) | 2026-04-09 | — | — | US | claimed |
| US-12594237-B2 | Mucoadhesive gel composition | Viramal Limited (GB) | 2026-04-07 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-4706674-A2 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING HEREDITARY ANGIOEDEMA ATTACK | Takeda Pharmaceutical Company Limited (JP) | 2026-03-11 | — | — | EP | claimed |
| EP-4525938-B1 | RADIOPHARMACEUTICAL COMPLEXES TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND ITS COMBINATIONS | BAYER AG (DE) | 2026-03-11 | — | — | EP | claimed |
| US-20260048013-A1 | PHARMACEUTICAL FORMULATION WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY | CONSEJO SUPERIOR INVESTIGACION (ES) | 2026-02-19 | — | — | US | claimed |
| EP-0330786-A1 | Topical drug delivery systems containing danazol | Igarashi, Masao (JP) | 1989-09-06 | — | — | EP | claimed |
| US-4852579-A | Photocharacterization and treatment of normal abnormal and ectopic endometrium | KARL STORZ ENDOSCOPY GMBH AND COMPANY (DE) | 1989-08-01 | — | — | US | claimed |
| US-4837212-A | Treatment of hemolytic anemia with danazol | UNIVERSITY OF MIAMI (US) | 1989-06-06 | — | — | US | claimed |
| US-4835146-A | Method of treating sickle cell anemia with danazol | UNIVERSITY OF MIAMI (US) | 1989-05-30 | — | — | US | claimed |
| EP-0310662-A1 | PHOTOCHARACTERIZATION AND TREATMENT OF NORMAL, ABNORMAL AND ECTOPIC ENDOMETRIUM | VANCAILLIE, Thierry Georges (US) | 1989-04-12 | — | — | EP | claimed |
| US-4783337-A | Osmotic system comprising plurality of members for dispensing drug | ALZA CORPORATION (US) | 1988-11-08 | — | — | US | claimed |
| WO-1988008273-A1 | PHOTOCHARACTERIZATION AND TREATMENT OF NORMAL, ABNORMAL AND ECTOPIC ENDOMETRIUM | VANCAILLIE THIERRY GEORGES (US) | 1988-11-03 | — | — | WO | claimed |
| EP-0142309-A2 | Method of preparing steroid compoundshaving a reduced particle size form | STERWIN AG. (CH) | 1985-05-22 | — | — | EP | claimed |
| US-4282218-A | ANTIANDROGENS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1981-08-04 | — | — | US | claimed |
| US-4055562-A | Process for preparing pregn-20-yne compounds and novel product produced thereby | STERLING DRUG INC. (US) | 1977-10-25 | — | — | US | claimed |